What is Ionis Pharmaceuticals's other — revenue?

Ionis Pharmaceuticals (IONS) reported other — revenue of $0 in Q2 2025.

What does other — revenue mean?

Revenue earned from non-core business activities or secondary segments outside of the company's primary product lines.

How do you interpret other — revenue?

An increase suggests successful monetization of secondary assets or expanded ancillary service offerings, while a decrease may indicate a strategic shift away from non-core activities or the sunsetting of minor programs.

How does other — revenue compare across companies?

Peers in the biotechnology sector often report similar 'Other' or 'Miscellaneous' revenue streams, which typically represent a small percentage of total revenue and are subject to lumpy, project-based recognition.

Ionis Pharmaceuticals IONS Other — Revenue

Discontinued — last reported Q2 '25

Other product segments

Research And Development Revenue

$138.28M+149%

Collaborative Agreement Revenue

$120.66M+168%

Commercial

$107.81M+41.5%

Royalty

$58.32M-9.1%

Spinraza Royalties

$43.71M-9.0%

Tryngolza

$27.1M+331%

Wainua Joint Development Revenue

$17.62M+69.2%

Wainus Royalties

$10.71M+14.3%

Other Commercial

$6.53M+14.3%

Other Royalties

$3.9M-42.5%

Similar metrics at other companies

VTRSOther Revenues — Revenue

$16.1M-32.9%

BIIBOther corporate revenues — Product revenues

$114.2M-20.6%

BIIBOther — Total Revenue

$55.4M+88.4%

BIIBOther — Revenue

$55.4M+88.4%

UTHROther — Total revenues

$5.3M+6.0%

INCYProduct And Service Other — Revenue

$58K+105%

Other financials

Income statement

See full

Revenue$246.1M+87.0%

Gross profit$243.1M+86.8%

Operating income-$117.4M+20.0%

Net income-$92.5M+37.0%

EPS (diluted)-$0.56+39.8%

Balance sheet

See full

Cash & equivalents$173.4M-34.4%

Total debt$691.7M+334%

Total equity$491.4M+3.3%

Total assets$3.4B+22.6%

Cash flow

See full

Operating cash flow-$792.8M-426%

CapEx$21.8M+73.0%

Free cash flow-$814.6M-399%

Valuation

See full

Market cap$12.25B+159%

Enterprise value$12.77B+175%

P/S11.6×+5.0×

Profitability

See full

Gross margin98.4%-0.2pp

Operating margin-33.3%-11.0pp

Net margin-30.9%-10.5pp

FCF margin-77.4%+35.3pp

Returns & leverage

See full

Return on equity-67.6%-20.3pp

Debt / equity1.4×+1.1×

Current ratio4.1×-5.6×

Where this comes from

Reported directly by Ionis Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Ionis Pharmaceuticals’s 10-Q, filed July 30, 2025, on SEC EDGAR. View the filing →

Ask your AI about Ionis Pharmaceuticals's other — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ionis Pharmaceuticals's other — revenue?: Ionis Pharmaceuticals (IONS) reported other — revenue of $0 in Q2 2025.
What does other — revenue mean?: Revenue earned from non-core business activities or secondary segments outside of the company's primary product lines.
How do you interpret other — revenue?: An increase suggests successful monetization of secondary assets or expanded ancillary service offerings, while a decrease may indicate a strategic shift away from non-core activities or the sunsetting of minor programs.
How does other — revenue compare across companies?: Peers in the biotechnology sector often report similar 'Other' or 'Miscellaneous' revenue streams, which typically represent a small percentage of total revenue and are subject to lumpy, project-based recognition.